Identification of anticancer drugs for hepatocellular carcinoma through personalized genome‐scale metabolic modeling

DOI PDF Web Site Web Site Web Site ほか1件をすべて表示 一部だけ表示 被引用文献3件

書誌事項

公開日
2014-03-01
権利情報
  • https://creativecommons.org/licenses/by/3.0/
  • https://creativecommons.org/licenses/by/3.0/
DOI
  • 10.1002/msb.145122
公開者
Springer Science and Business Media LLC

説明

<jats:title>Abstract</jats:title> <jats:p> Genome‐scale metabolic models (GEMs) have proven useful as scaffolds for the integration of omics data for understanding the genotype–phenotype relationship in a mechanistic manner. Here, we evaluated the presence/absence of proteins encoded by 15,841 genes in 27 hepatocellular carcinoma (HCC) patients using immunohistochemistry. We used this information to reconstruct personalized GEMs for six HCC patients based on the proteomics data, HMR 2.0, and a task‐driven model reconstruction algorithm (tINIT). The personalized GEMs were employed to identify anticancer drugs using the concept of antimetabolites; i.e., drugs that are structural analogs to metabolites. The toxicity of each antimetabolite was predicted by assessing the <jats:italic>in silico</jats:italic> functionality of 83 healthy cell type‐specific GEMs, which were also reconstructed with the tINIT algorithm. We predicted 101 antimetabolites that could be effective in preventing tumor growth in all HCC patients, and 46 antimetabolites which were specific to individual patients. Twenty‐two of the 101 predicted antimetabolites have already been used in different cancer treatment strategies, while the remaining antimetabolites represent new potential drugs. Finally, one of the identified targets was validated experimentally, and it was confirmed to attenuate growth of the HepG2 cell line. </jats:p>

収録刊行物

被引用文献 (3)*注記

もっと見る

問題の指摘

ページトップへ